U.S. stock market update: Boston Scientific acquires Penumbra for $14.5 billion, stock price surges 12.15%, attracting market attention!

U.S. Stock Market Midday Update Penumbra rose 12.15%, with increased trading volume. Based on recent key news: On January 15, Boston Scientific announced the acquisition of Penumbra for $14.5 billion, with the deal expected to close in 2026. This news drove Penumbra's stock price up by 11.5%. On January 15, Penumbra's pre-market stock price soared 13.3% due to Boston Scientific's announcement of the acquisition plan, which values Penumbra at $374 per share, a 19.3% premium over the previous day's closing price. On January 15, Penumbra's stock price rose 10% in pre-market trading, while Boston Scientific's stock price fell 4%. The medical device industry has recently performed strongly, with frequent acquisition activities. Top Stocks by Industry Trading Volume Boston Scientific fell 4.60%. Based on recent key news: On January 15, Boston Scientific announced the acquisition of Penumbra for $14.5 billion, leading to a drop in its stock price. This deal aims to expand its vascular product line, while Penumbra's stock price rose 11.5%. Source: Reuters On January 15, there was active defensive buying for Boston Scientific, with funds flowing into medical blue-chip stocks, indicating risk-averse sentiment. Source: Zhitong Finance On January 15, Boston Scientific plans to finance the acquisition through cash and new debt, maintaining flexibility for potential mergers and acquisitions. Source: WSJ The medical industry is seeing funds flow into blue-chip stocks, with strong risk-averse sentiment. Intuitive Surgical fell 1.34%. Based on recent key news: On January 15, Intuitive Surgical released preliminary fourth-quarter results, and although revenue exceeded expectations, the guidance for procedure growth was below market expectations, leading to a 3.8% drop in stock price. Analysts noted that global usage growth has plateaued, and the company's 2026 guidance is somewhat conservative, which may affect investor confidence. Source: WSJ On January 14, Intuitive Surgical projected revenue of approximately $10.06 billion for 2025, a 21% increase from 2024. Despite strong revenue growth, the market has high expectations for future growth, putting pressure on the stock price. Source: Reuters On January 14, analysts maintained a buy rating with a target price of $740, reflecting market confidence in the company's long-term growth potential, but the stock price remains influenced by performance guidance in the short term. Source: TipRanks The medical device industry has recently shown volatility, requiring attention to policy changes. Abbott fell 0.82%. Abbott fell 0.82%. No significant news recently; trading is active, with clear fund flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news Top Stocks by Industry Market Capitalization Stryker rose by 0.37%. Based on recent key news: On January 15, Benzinga reported an increase in insider trading activity at Stryker, particularly involving options conversions and securities grants. These transactions may indicate internal confidence in the company's future performance, driving the stock price up. On January 14, analysts rated Stryker as "Moderate Buy," but it was not included in the top recommended stocks list. This indicates a cautious market attitude towards its short-term performance, which may limit further increases in the stock price. The medical device industry has shown stable performance recently